Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Scripps Research Scientists Devise Powerful New Method for Finding Therapeutic Antibodies

12.09.2012
The Technique Hones and Expands the Power of Large Numbers

Scientists at The Scripps Research Institute have found a new technique that should greatly speed the discovery of medically and scientifically useful antibodies, immune system proteins that detect and destroy invaders such as bacteria and viruses.

New methods to discover antibodies are important because antibodies make up the fastest growing sector of human therapeutics; it is estimated that by 2014 the top-three selling drugs worldwide will be antibodies.

The new technique, described in an article this week published online ahead of print by the journal Proceedings of the National Academy of Sciences, enables researchers to search large libraries of antibodies and quickly select the ones with a desired biological effect. It also provides for the creation of unusual, asymmetric antibodies whose capabilities extend beyond those of natural antibodies. The Scripps Research scientists demonstrated the power of the technique by using it to find an asymmetric antibody that almost perfectly mimics the activity of erythropoietin (EPO), a medically valuable hormone.

“Traditionally we’ve looked at antibodies as tools for binding to specific targets, but we should view them more generally, as tools for probing and altering functions in cells,” said Richard Lerner, the Lita Annenberg Hazen Professor of Immunochemistry and member of the Department of Molecular Biology at Scripps Research who led the new study.

At the Vanguard
Lab-grown antibodies already represent a major part of the ongoing biotechnology revolution. Used as scientific probes or medical therapies, they recreate the versatility of natural antibodies, which are produced by immune cells in a vast diversity to bind to highly specific shapes on viruses, bacteria, and other targets.
Two decades ago, Lerner and his laboratory at Scripps Research, in parallel with the group of Sir Gregory Winter at the Laboratory of Molecular Biology in Britain, developed the first techniques for generating very large libraries of combinatorial antibodies and quickly isolating those that can bind to a desired target. Since then, such techniques have been used to find antibodies to treat cancer, arthritis, transplant rejection, and other conditions. Humira, an anti-inflammatory antibody that was discovered this way, is expected to be the world’s top-selling drug this year. Belimumab (Benlysta®) was approved by the US Food and Drug Administration in 2011 to treat lupus, becoming the first new drug to treat the chronic, life-threatening inflammatory disease in more than 50 years.

Current antibody-discovery techniques have one big drawback, however. Although they can rapidly find antibodies that bind tightly to a known target, they can’t rapidly determine which of those antibodies has useful biological activity. An antibody may bind tightly to a virus without affecting the virus’s ability to infect cells, for example, or it may bind to a cellular receptor without activating that receptor. With current techniques, determining the overall biological effect of a target-binding antibody typically requires further, painstaking analysis.

A More Direct Path

In the new study, Lerner and his postdoctoral researcher Hongkai Zhang sought a method for rapidly finding antibodies that have a desired effect on cells, not just a desired ability to bind to a target. As a proof of principle, they aimed to discover an antibody that could mimic the activity of EPO, a hormone that stimulates red blood cell production. Drugs that mimic EPO’s effect are commonly used to treat anemia and related conditions.

Zhang began by using traditional techniques to quickly sift through a large antibody library to find tens of thousands of antibodies that bind tightly to the EPO receptor. He then stepped beyond traditional techniques, by taking the genes that encoded these EPO-receptor-binding antibodies and inserting them into lentiviruses. Unlike the phage viruses used in traditional methods, lentiviruses can usefully infect mammalian cells, delivering their payloads – antibodies, in this case – into a more human-like cellular environment.

Zhang applied this new library of antibody-coding lentiviruses to a single, large culture of mammalian test cells. The cells were of a type that express EPO receptors and proliferate when these receptors are bound by EPO proteins – or by antibodies that effectively mimic EPO. Each of these cells could host only a few viral particles at most, so in this way Zhang was able to distribute the entire library of EPO-receptor-binding antibodies broadly within the cell culture. Zhang also cultured the cells in a special way that prevented antibodies secreted by one cell from spreading easily to nearby cells and muddying any cause-effect relationship. “This concern over the diffusion of antibodies in the culture was one of the factors that had discouraged other researchers from using such a technique,” said Zhang.

After the lentiviruses had delivered the antibodies to the cultured cells, Zhang was able to note which cells were proliferating the most – signifying the presence of antibodies that mimic EPO. To identify the antibodies responsible, Zhang had only to harvest these faster-growing cells and sequence the antibody genes inside them.

This method quickly yielded an antibody that in a further test showed about 60 percent of the biological activity of natural EPO – which was as good as any antibody EPO-mimic that had ever been described.
Opening the Door to the Unknown

But Zhang and Lerner also noted that many of the proliferating cells had been infected by multiple lentivirus particles, and contained sequences from more than one antibody. Puzzlingly, Zhang found that when he recreated antibodies from these sequences, and tested them individually or in combinations, they showed no significant EPO-mimicking effect. Further tests showed that the source of the EPO-mimicking effect in the test cells was an antibody that does not occur naturally.

An antibody of the type used in the study has a Y-shaped structure, normally with two identical binding arms. But the presence of multiple antibody genes within some of Zhang’s test cells meant that, in a few cases, antibodies assembled themselves with two different binding arms. One of these “bispecific” antibodies turned out to bind to the EPO receptor – which has two binding sites – in a way that very accurately mimics the binding of a natural EPO molecule. “It turned out to be 100 percent as potent as authentic EPO in further tests,” Zhang said.

The serendipitous finding represents another major innovation, for, in principle, it extends the medical and scientific antibody repertoire from the 100 billion or so known variants of same-armed antibodies to an astronomically higher number of bispecific variants. Experiments to test such variants will be limited by the maximum number of usable cells in cultures, but that number is still very high, on the order of 10 million. “That allows for a lot of unique binding events,” said Lerner. “You probably can get almost anything that way.”

Lerner emphasizes that this new antibody-engineering/discovery technique can be used not just against known targets such as the EPO receptor, but also against cellular functions involving targets that have not yet been found. “The real power of this technique is its ability to help us discover the unknown,” he said.

Another author of the study, titled “Selection of antibodies that regulate phenotype from intracellular combinatorial antibody libraries,” was Ian A. Wilson, the Hansen Professor of Structural Biology at Scripps Research and an expert on the structure of the EPO receptor. For more information on the paper, see http://www.pnas.org/content/early/2012/09/05/1214275109.abstract

About The Scripps Research Institute

The Scripps Research Institute is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. Over the past decades, Scripps Research has developed a lengthy track record of major contributions to science and health, including laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. The institute employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards Ph.D. degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
For information:
Office of Communications
Tel: 858-784-8134
Fax: 858-784-8136
press@scripps.edu

Mika Ono | EurekAlert!
Further information:
http://www.scripps.edu

More articles from Health and Medicine:

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

nachricht A promising target for kidney fibrosis
21.04.2017 | Brigham and Women's Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Scientist invents way to trigger artificial photosynthesis to clean air

26.04.2017 | Materials Sciences

Ammonium nitrogen input increases the synthesis of anticarcinogenic compounds in broccoli

26.04.2017 | Agricultural and Forestry Science

SwRI-led team discovers lull in Mars' giant impact history

26.04.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>